RhoB and FoxO3a Signaling in Anaplastic Thyroid Carcinoma

Image of a Western blot examining induced RhoB expression

Western blot examining induced RhoB expression in response to five different classes of drugs in anaplastic thyroid carcinoma

RhoB, a member of the Ras superfamily of isoprenylated small GTPases, is not mutated but rather attenuated in cancer. Consequently, inducing RhoB expression in aggressive cancers, such as anaplastic thyroid carcinoma, inhibits growth and induces cell death.

RhoB also enhances cell death when combined with other chemotherapeutics. Upregulation of RhoB can then be used as a biomarker since it is a key modulator for responsiveness.

In fact, preclinical data on CS-7017, a PPARgamma agonist generated in the Cancer Biology and Translational Oncogenomics Laboratory, led to a combinatorial clinical trial with Daiichi Sankyo Co. In addition to finding reagents that induce RhoB, the lab also wants to define the mechanism by which RhoB inhibits proliferation and induces apoptosis in cancer.